Can Vanda Pharmaceuticals Inc. (VNDA)’s Tomorrow Be Different? The Stock Increases Again

February 23, 2018 - By Kurt Siggers

Investors sentiment increased to 1.43 in Q3 2017. Its up 0.26, from 1.17 in 2017Q2. It is positive, as 12 investors sold Vanda Pharmaceuticals Inc. shares while 34 reduced holdings. 21 funds opened positions while 45 raised stakes. 38.89 million shares or 4.39% more from 37.25 million shares in 2017Q2 were reported.
Ajo L P stated it has 0.04% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Invesco reported 409,835 shares. Gagnon Securities reported 0.12% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Point72 Asia (Hong Kong) holds 0% or 59 shares in its portfolio. Fmr Ltd reported 0% stake. 59,338 were accumulated by Jpmorgan Chase. Ny State Common Retirement Fund holds 53,370 shares or 0% of its portfolio. Balyasny Asset Management Ltd Liability Co reported 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). State Street stated it has 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Strs Ohio, a Ohio-based fund reported 44,100 shares. Weiss Multi holds 55,000 shares. Us Commercial Bank De accumulated 300 shares. Sg Americas Limited Liability Company accumulated 8,828 shares. Ameriprise Fin holds 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 88,160 shares. Sei Investments Communications invested 0.02% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Since January 2, 2018, it had 0 buys, and 4 selling transactions for $3.36 million activity. 9,155 Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares with value of $140,494 were sold by Kelly James Patrick. $130,777 worth of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was sold by Birznieks Gunther on Tuesday, January 2. Polymeropoulos Mihael Hristos sold $2.93 million worth of stock or 191,760 shares.

The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is a huge mover today! The stock increased 6.23% or $1.1 during the last trading session, reaching $18.75. About 729,046 shares traded or 41.22% up from the average. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 51.60% since February 23, 2017 and is uptrending. It has outperformed by 34.90% the S&P500.
The move comes after 8 months positive chart setup for the $851.96M company. It was reported on Feb, 23 by Barchart.com. We have $19.88 PT which if reached, will make NASDAQ:VNDA worth $51.12 million more.

Analysts await Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report earnings on May, 1. They expect $-0.14 earnings per share, up 17.65 % or $0.03 from last year’s $-0.17 per share. After $-0.04 actual earnings per share reported by Vanda Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 250.00 % negative EPS growth.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Among 8 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda Pharmaceuticals had 22 analyst reports since September 2, 2015 according to SRatingsIntel. The rating was maintained by Jefferies with “Buy” on Monday, September 4. The company was maintained on Tuesday, February 13 by Jefferies. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has “Buy” rating given on Thursday, October 6 by Jefferies. As per Wednesday, September 2, the company rating was maintained by Piper Jaffray. Aegis Capital initiated the stock with “Buy” rating in Wednesday, November 9 report. As per Thursday, August 3, the company rating was maintained by Oppenheimer. The rating was initiated by Brean Capital with “Buy” on Wednesday, October 21. Piper Jaffray maintained the stock with “Buy” rating in Thursday, October 19 report. JMP Securities maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Wednesday, March 9 with “Market Outperform” rating. On Thursday, August 3 the stock rating was maintained by H.C. Wainwright with “Buy”.

More news for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) were recently published by: Prnewswire.com, which released: “Vanda Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial …” on February 14, 2018. Prnewswire.com‘s article titled: “Quotidian Technical Highlights on Selected Biotech Stocks — Tesaro, Trevena …” and published on February 21, 2018 is yet another important article.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $851.96 million. The companyÂ’s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It currently has negative earnings. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.